| abstract |
The present disclosure relates to methods for treating or preventing a liver disease, using a LTA4H inhibitor, alone or in combination with another therapeutic agent, e.g. a FXR agonist. Also disclosed herein are LTA4H inhibitors, for treating or preventing a liver disease or disorder, as well as medicaments, dosing regimens, pharmaceutical formulations, combinations, dosage forms, and kits for use in the disclosed uses and methods. |